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Peptide libraryalian cells, the nucleocapsid (N) and membrane (M) proteins of the severe acute
respiratory syndrome coronavirus (SARS-CoV) are sufﬁcient to form pseudoparticles. To identify region(s) of
the N molecule required for pseudoparticle formation, we performed biochemical analysis of the interaction
of N mutants and M in HEK293 cells. Using a peptide library derived from N, we found that amino acids 101–
115 constituted a novel binding site for M. We examined the ability of N mutants to interact with M and form
pseudoparticles, and our observations indicated that M bound to NΔ(101–115), N1–150, N151–300, and
N301–422, but not to N1–150Δ(101–115). However, pseudoparticles were formed when NΔ(101–115) or
N301–422, but not N1–150 or N151–300, were expressed with M in HEK293 cells. These results indicated
that the minimum portion of N required for the interaction with M and pseudoparticle formation consists of
amino acids 301–422.
© 2008 Elsevier Inc. All rights reserved.Introduction
Severe acute respiratory syndrome (SARS), caused by a newly
identiﬁed coronavirus (SARS-CoV), has been observed in about 30
countries, affecting more than 8,000 people and resulting in death in
about 10% of cases (Guan et al., 2003). SARS-CoV was identiﬁed as a
novel type of coronavirus, differing from known coronaviruses (Guan
et al., 2003; Marra et al., 2003; Rota et al., 2003). The genome and
functional receptor of SARS-CoV have been identiﬁed (Li et al., 2003),
but no vaccine or drug treatment has yet been approved. Although
bats carry viruses similar to SARS-CoV (Wang et al., 2006), its natural
host has not yet been identiﬁed.
Coronaviruses have a positive single-stranded RNA genome of
approximately 30 kb that encodes structural proteins, such as the
spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins.
The S protein encoded by SARS-CoV, a large type-I transmembrane
glycoprotein, is necessary for binding and fusion to host cells. S
protein consists of the N-terminal S1 domain, which binds humaniyama).
l rights reserved.angiotensin-converting enzyme 2 (ACE2), a functional receptor for
SARS-CoV (Li et al., 2003), and a C-terminal S2 domain that mediates
the fusion of viral and host cell membranes (Tripet et al., 2004;
Xu et al., 2004).
The E protein, a type-II transmembrane glycoprotein, is the
smallest structural protein in SARS-CoV (Wu et al., 2003). Although
required for the formation of pseudoparticles in insect cells (Mortola
and Roy, 2004), E is not necessary to form pseudoparticles in
mammalian cells (Huang et al., 2004). E acts as a cation-selective
ion channel (Wilson et al., 2004). rSARS-CoV-ΔE has been shown to
replicate to titers 100- to 1000-fold lower than recombinant wild-type
virus in vivo, although both viruses show the same morphology and
stability at severe pH and temperature (DeDiego et al., 2007).
TheM protein consists of a short N-terminal ectodomain harboring
an N-glycosylation site, three transmembrane domains and a long
cytoplasmic tail (Hu et al., 2003), and a C-terminal domain (residues
194–205 or 197–221) that binds to N (Fang et al., 2005; Luo et al.,
2006b). M is essential for the formation of pseudoparticles (Huang et
al., 2004). In the case of murine coronavirus, only M and E are required
for formation of pseudoparticles (Bos et al., 1996; Vennema et al.,
1996), in marked contrast with the case of SARS-CoV requiring M and
N only to form pseudoparticles (Huang et al., 2004).
Fig. 1. Interaction of N-derived peptides with M protein. (A) Each peptide (10 μg/mL) was immobilized on ELISA plates. After blocking, the plates were incubated with M63 (ﬁnal
1 μg/mL), and binding of M63 to N protein was detected with rabbit anti-M63 plus HRP-goat anti-rabbit IgG. The two data points for each peptide are the results of two independent
experiments. (B) Each peptide (10 μg/mL) was injected into a BIAcore ﬂow cell containing immobilized M116. The injection was started at 100 s, stopped at 240 s, and dissociated for
300 s. (C) Competitive inhibition of binding between N and M63 proteins by N-derived peptides. M63 was preincubated with each N peptide, and each mixture was added to a plate
coated with N protein. Binding of M63 to N protein was detected as in (A). Binding in the absence of peptide was set at 100%. Data are presented as means±SD.
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that plays a role in virion assembly through its interactions with the
viral genome and M protein (Hurst et al., 2005; Masters, 1992; Nelson
and Stohlman, 1993; Narayanan et al., 2000; Narayanan et al., 2003).
The N protein is also considered essential for viral RNA synthesis,
although the cellular events affected by N are not yet known (Almazan
et al., 2004). Crystal structures of C-terminal domain (amino acids
248–365) (Chen et al., 2007), N-terminal domain (amino acids 1–174)Fig. 2. Schematic diagram of the recombinant N andM proteins used in this study. N mutants
consist of the C-terminal 116 and 63 amino acids of M, respectively.(Saikatendu et al., 2007) and dimerization domain (amino acids 270–
370) (Yu et al., 2006) have been reported. N contains a disordered
region in the middle of the molecule (Chang et al., 2006; Zuniga et al.,
2007), which does not form a particular structure otherwise it binds
adequate binding partners.
Virion formation is the fundamental process in viral replication,
and results from the interactions between viral proteins under
physiological conditions. The expression of M, E, and S in Sf9 insectare numbered according to the amino acid positions in the full-length N. M116 andM63
Fig. 3. Analyses of interactions between N mutants and M and the inhibition by peptide 101–115. (A) ELISA of the interaction between N mutants and M116. Each N peptide (0.01–
10 μg/mL) was immobilized onto a plate. After blocking, the plate was incubated with M116 (1 μg/mL), and bound M116 was detected with rabbit anti-M63 and HRP-goat anti-rabbit
IgG as described in Materials and methods. (B) Inhibition of the interaction between N mutants and M116 was observed with peptide 101–115. The experimental procedure was
identical to that described in the legend to Fig. 1C. Data are presented as means±SD.
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2004), whereas, only M and N were required in mammalian cells
(Huang et al., 2004). Replication of SARS-CoV may be controlled by
modifying the interaction between the M and N proteins. Using aFig. 4. Immunoprecipitation analyses of the interaction between Nmutants andM116 in mam
days post-transfection was performed as described in Materials and methods. (B,C) Immu
antibodies of lysates of HEK293 cells coexpressing N mutants and M116. As both of the antib
rabbits, the immunoglobulin light chain (ca. 25 kDa) was observed due to cross-reaction wmammalian two-hybrid system, the region of N bound to M (amino
acids 168–208) was found to contain a serine/arginine-rich motif
(amino acids 184–196) (He et al., 2004b). The same region was
necessary for self-multimerization of N (He et al., 2004a). Analysismalian cells. (A)Western blotting of the lysates of HEK293 cells expressing Nmutants 3
noprecipitation analyses using control antiserum (C), anti-M63 (M63), or anti-N (N)
odies used for immunoprecipitation and detection of the target proteins were raised in
ith the 2nd antibody.
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techniques showed that amino acids 351–422 of N interacted with
amino acids 197–221 of M and that the C-terminal region of N (amino
acids 343–402) was necessary for its oligomerization (Luo et al.,
2006b).
In the present study, we identiﬁed a novel binding region for M in
N and conﬁrmed the interaction between this region of N and M in
mammalian cells. We also found that interaction of the C-terminal
portion of N with M was sufﬁcient to form pseudoparticles in
mammalian cells.
Results
Identiﬁcation of regions in N that bind M
To identify the site(s) in the N protein that bind to M protein, we
employed an overlapping peptide library covering the entire N
protein. The peptides were immobilized onto ELISA plates, and
binding of M63 to these peptides was analyzed using anti-M63
antibody. The M63 reacted with an N-terminal peptide corresponding
to amino acids 101–115 and to 5 C-terminal peptides, corresponding
to amino acids 291–305, 301–315, 321–335, 351–365, and 361–375
(Fig. 1A). In SRP analysis, two peptides corresponding to amino acids
101–115 (KMKELSPRWYFYYLG) and 321–335 (IGMEVTPSGTWLTYH)
showed binding to M116 (Fig. 1B). For peptide 101–115, the binding to
M116 was dose-dependent, with a Kd of 0.73 μM (data not shown).
To analyze whether the N-derived peptides compete with N itself
in the interaction between M and N proteins, these peptides were
incubated with M63 and subsequently added to ELISA plates contain-
ing immobilized N protein. Using anti-M63 antibody, we found that
only peptide 101–115 signiﬁcantly inhibited the interaction between
M63 and N protein, whereas peptides 291–305, 301–315, 321–335,Fig. 5. Assembly of pseudoparticles in transfected HEK293 cells. (A) Gradient sedimentatio
transfected N mutants alone were performed 3 days after transfection, as described in Mat
Arrows indicate the positions of M and N mutants. In the top panel, N and M were detected
used in the bottom panel. (B) Analysis of viral assembly of mutants of N and M proteins by T
described in Materials and methods. The areas in the white squares indicate the areas mag341–355, 351–365, and 361–375 did not inhibit this interaction (Fig.
1C), nor did mixtures of peptides 291–305, 301–315, 341–355, 351–
365, and 361–375 and peptides 91–105 and 111–125 (data not shown).
Binding of N mutants to M
The middle region of N contains a serine/arginine-rich motif,
which has been reported to interact with M and to mediate N protein
self-oligomerization (He et al., 2004b), whereas the C-terminal region
of N contains domains involved in N protein self-oligomerization, RNA
binding, and M protein binding (He et al., 2004a). The region
comprised of amino acids 101–115 of N, however, has not been
thought to interact with M. To dissect the interaction of N with M,
several N protein mutants were constructed: N1–150, N151–300,
N301–422, N1–150Δ(101–115), and N(full)Δ(101–115) (Fig. 2). Using
ELISA-based analyses (Fig. 3), M116 bound to N(full), N(full)Δ(101–
115), and to a lesser extent to N1–150, N151–300, and N301–422, in a
dose-dependent manner. In contrast, N1–150Δ(101–115) did not
show signiﬁcant binding to M116. These results indicated that all
three portions of N (1–150, 151–300, and 301–422) can bind M, and
that the binding of N1–150 is mediated by residues 101–115.
Binding of N mutants to M in mammalian cells
We also analyzed the interaction of N mutants and M coexpressed
in HEK293 cells by immunoprecipitation using antibodies against
anti-M63 or anti-N proteins from lysate prepared from HEK293 cells
expressed the N mutants and full-length M protein (Fig. 4). As the N
mutants bound to the Protein G Sepharose without addition of any
antibodies, we preincubated the cell lysate with Protein G Sepharose
to reduce background binding. Immunoprecipitation experiments
using anti-M63 antibody showed that N(full), NΔ(101–115), N1–150,n analyses of pseudoparticles from cell lysates transfected with M and N mutants or
erials and methods. Fractions are numbered from the top of each tube (lower density).
simultaneously by anti-M63 antiserum and anti-N serum, while only anti-N serumwas
EM. TEM analysis was performed on HEK293 cells transfected with N mutants and M as
niﬁed and shown in the respective lower panels.
Fig. 5 (continued).
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Although N(full), NΔ(101–115), and N301–422 were immunoprecipi-
tated with control serum even after pretreatment of the lysate with
Protein G Sepharose, the amounts precipitated were increased using
anti-M63. In contrast, only N1–150Δ(101–115) was not immunopre-
cipitated by anti-M63 antibody. Using anti-N antibody (Fig. 4C), M116
was immunoprecipitated along with N(full), NΔ(101–115), N1–150,
N151–300, and N301–422, but not with N1–150Δ(101–115). These
results suggested that all portions of N except N1–150Δ(101–115) can
interact with M116 in mammalian cells.
Pseudoparticle formation by N mutants and M in 293 cells
We investigated whether the interaction of several N mutants and
M protein would lead to formation of pseudoparticles (Fig. 5). In
buoyant density gradient analysis, N was present around fractions 6–
13 when N alone was expressed in HEK293 cells (Fig. 5A). In contrast,
when N was coexpressed with M, N was present in fractions 4–6, the
main fractions containing M, as well as in fractions 7–14, indicating
the formation of pseudoparticles (Huang et al., 2004). When N
mutants were expressed alone in 293 cells, they were detected in
fractions 7–14. When coexpressed with M, N(full), NΔ(101–115), andN301–422 were located in fractions 3–5, along with M. In contrast,
N1–150, N1–150Δ(101–115), and N151–300 were not located in
fractions containing M.
We used transmission electron microscopy (TEM) to determine
whether pseudoparticles were formed by the coexpression of N
mutants and M proteins in HEK293 cells (Fig. 5B). When N(full) and M
were coexpressed in HEK293 cells, pseudoparticles of about 80 nm in
size, the same size as SARS-CoV virions, appeared between the
endoplasmic reticulum (ER) and Golgi bodies (Huang et al., 2004).
When the N mutants N1–150, N1–150Δ(101–115), and N151–300
were coexpressed with M, pseudoparticles were not observed,
whereas pseudoparticles were observed when NΔ(101–115) and
N301–422 were coexpressed with M. The pseudoparticles observed
were 60–80 nm in diameter (Fig. 5B). These results indicated that the
C-terminal portion of N, consisting of amino acids 301–422, is
necessary and sufﬁcient for the formation of pseudoparticles with M.
Inhibition of the binding of N mutants to M by the 101–115 peptides
To determine the region in peptide 101–115 critical for the
inhibition, we assessed the abilities of 10-mer peptides spanning
amino acids 101–115 of N (Fig. 6A) to inhibit the interaction between N
Fig. 5 (continued).
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interaction between N and M (Fig. 6B). Using peptides containing a
shufﬂed amino acid sequence of pep10, we found that pep18 partially
inhibited the M–N interaction, whereas pep16 and pep17 did not (Fig.
6C). These results indicated that the motif “PRWYFYYLG” was critical
for inhibition, and that inhibitionwas at least partly sequence-speciﬁc
and not nonspeciﬁc.We also examined whether the 101–115 peptide interferes with
the interaction between N mutants and M in ELISA format (Fig. 3B).
Surprisingly, the 101–115 peptide inhibited the binding to M by N
mutants that did not contain the corresponding sequence (NΔ101–115
and N1–150Δ101–115). As shown in Fig. 2, the peptides bound to M
directly. Taken together, these results suggested that the mode of
inhibition of the interaction between N and M by the 101–115 peptide
Fig. 6. Determination of the critical residues in N peptide 101–115 that inhibit the interaction between M and N. (A) Peptide sequences used in the analysis. Pep1 is the 101—115
peptide itself. Pep6 to Pep15 are 10-mer peptides spanning amino acids 101–115 of N. Pep16 to Pep18 are sequence-scrambled versions of Pep10. Amino acid sequences of Pep8 to
Pep10, which showed strong inhibitory effects on the interaction between N and M in (B) are indicated in a box. (B) Ability of the 10-mer peptides derived from N peptide 101–115 to
inhibit the interaction between N andM. The indicated peptides were analyzed for their ability to inhibit the interaction between N andM, as described inMaterials andmethods. (C)
Abilities of the 10-mer scrambled versions of the peptides to inhibit the interaction between N and M. Binding in the absence of peptide was set at 100% (not shown). Data are
presented as means±SD.
105S. Hatakeyama et al. / Virology 380 (2008) 99–108is occupation of the N binding site onM and not simple competition of
101–115 with the corresponding sequence in N.
Discussion
Due to the lack of an effective method of treatment or a vaccine for
SARS, it is necessary to develop drugs that inhibit viral replication and/
or transmission. One possible target is inhibition of virion formation.
In mammalian cells, the interaction between N and M, the major
structural proteins of SARS-CoV, is critical for the formation of
pseudoparticles (Huang et al., 2004). To dissect this interaction at
the sub-molecular level, we analyzed the interaction of M with
peptides derived from N, and found that 101–115 showed signiﬁcant
binding to M. We also examined whether various N peptides could
interact with M protein to form pseudoparticles. The results of the
present study indicated that although N peptides 1–150, 151–300, and
301–422 can bind to M, only the latter is required for pseudoparticle
formation.
The results of studies to assign the functional regions in N showed
that N151–300 contains the SR-rich region that binds to M (168–208)
(He et al., 2004b) as well as being important for the formation of N-
dimers (Saikatendu et al., 2007). The N301–422 region contains a site
(amino acids 351–422) that interacts with M sites (amino acids 343–
363 and 382–402) for self-association (Luo et al., 2006a, 2006b). The N
peptides 211–422 and 285–422 efﬁciently formed dimers, and dimeric
N proteins associated into tetramers (Luo et al., 2006a). In the present
study, biochemical analyses of recombinant proteins and coexpression
analysis in mammalian cells showed that all regions of N interacted
with M, and identiﬁed an as yet unreported region, amino acids 101–
115, that also interacted with M.
Analysis of pseudoparticle formation by isolated proteins would
provide critical clues into the process of virion formation in vivo. In
mammalian cells, the formation of SARS-CoV pseudoparticles requires
a minimum of two proteins, N and M (Huang et al., 2004). Using
buoyant density gradient analysis and TEM, we observed pseudopar-
ticle formation when M was coexpressed with N wild-type, NΔ(101–
115), or N301–422 in HEK293 cells, indicating that the N protein
segment of amino acids 301–422 was the minimum requirement for
pseudoparticle formation. Based on these ﬁndings, we propose amodel for the assembly of SARS-CoV pseudoparticles by N and M (Fig.
7). N1–150 binds to M via the 101–115 region, as demonstrated in this
study. N151–300 binds to M via the 168–208 region as reported
previously (He et al., 2004b). N151–300 is also capable of forming
homodimers but not oligomers. However, this binding is not sufﬁcient
to support pseudoparticle formation in mammalian cells (Fig. 5B). In
contrast, N301–422 is capable of forming pseudoparticles. The
differences among the N regions are probably based on the ability to
form homooligomers. N301–422 contains a region capable of
homotetramer formation (He et al., 2004a). The tetramers of N
would provide scaffolds for the formation of pseudoparticles for M.
Indeed, N colocalized with M in buoyant density gradients formed
SDS-resistant oligomers (data not shown).
We found that peptides derived from amino acids 101–115 of N
inhibited the interaction between N and M. However, this ﬁnding was
partially contradictory as this region is fully dispensable for pseudo-
particle formation. Based on the crystal structure, the peptide is
located in the interior of N (Saikatendu et al., 2007). Thus, it is likely
that the peptide region has a quite limited role in pseudoparticle
formation.
Despite the limited role in pseudoparticle formation, the peptide
showed a strong inhibitory effect on the interaction between N and M
in vitro. We examined the abilities of these peptides to inhibit
pseudoparticle formation by N and M via either peptide delivery or
expression. However, these approaches were not successful (data not
shown), which may have been due to ineffective delivery and
insufﬁcient expression of the peptides, respectively. Interestingly,
the peptide (101–115) also inhibited the interaction between M and
other N mutants, not containing the 101–115 region. Recombinant
cytoplasmic region of the M protein used in this study consisted of
only 116 amino acid residues. Thus, one possibility to explain this
phenomenon is that M has only one site to bind N in the molecule and
the site is shared by several regions in N for their interaction; the 101–
115 peptide may occupy this site to inhibit access of N to M.
As the amino acid composition of the 101–115 peptide is
relatively hydrophobic, it is possible that the observed inhibitory
effect against the interaction between N and M may be nonspeciﬁc.
However, scrambled versions of the peptide, especially pep16 and
pep17, lost the ability to inhibit the interaction, indicating that the
Fig. 7. Schematic model for the assembly of pseudoparticles by N and M of SARS-CoV. Three portions of N have been shown to interact with M, corresponding to residues 101–115
(hatched), 168–208 (striped), and 351–422 (stippled) (He et al., 2004a, 2004b; Luo et al., 2006b), but only interaction via the C-terminal of N led to formation of pseudoparticles. The
351–422 region can also form N tetramers, and thus may provide a scaffold for the stable interaction between N and M, allowing pseudoparticle formation.
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inhibitory effect observed with another scrambled version of the
peptide, pep18, may have been because this peptide had a relatively
large percentage of hydrophobic residues, which may be exchange-
able to some extent.
In conclusion, we have shown here that theminimum requirement
of N protein to form pseudoparticles with M are amino acid residues
301–422, and that a peptide derived from amino acids 101–115 of N
may be a useful starting point to design molecule(s) to inhibit the
formation of SARS-CoV virions. These ﬁndings will advance our
understanding of the assembly of SARS-CoV and may facilitate the
development of anti-SARS-CoV drugs.
Materials and methods
Preparations of mutant N proteins
All N-derived constructs used in this study are presented in Fig. 2.
All of the plasmids expressing N mutants in Escherichia coli were
prepared using pDEST17 (Invitrogen), which carries a recognition site
for AcTEV protease (Invitrogen). pDEST17-SAR1262TEV encoding
wild-type N protein was constructed by a commercial service
(Invitrogen) and used as a template for PCR to amplify the various
N-derivatives. A plasmid VRC8303 carrying codon-optimized N was
kindly provided by Dr. Nabel of the National Institutes of Health
(Huang et al., 2004) and used as a template for PCR to amplify N-
derivatives for expression in mammalian cells. All constructs, with the
exception of mutants carrying deletions of amino acids 101–115, were
prepared by subcloning of the PCR products ampliﬁed using the
primer pairs listed in Table S1 and Pfx polymerase (Invitrogen). To
construct mutants with deletions of amino acids 101–115, N-terminaland C-terminal fragments not containing the deletion were ampliﬁed
separately by PCR using the primers listed in Table S1 and Pfx
polymerase. The PCR products were subsequently puriﬁed, mixed, and
used as a template for PCR ampliﬁcation of the entire fragment
carrying the deletion using Taq polymerase (Takara). For Gateway
cloning (Invitrogen), the PCR products were cloned using a TOPO
cloning kit (Invitrogen), digested from the resulting plasmids with
EcoRI and subcloned into pDONR221 by BP recombination in
accordance with the manufacturer's instructions. After antibiotic
selection, the fragments were introduced into pDEST17 by LR
recombination and used to transform TOP10 in accordance with the
manufacturer's protocol. The resulting plasmids were introduced into
E. coli strain BL21-AI (Invitrogen) to express the N mutants. PCR
fragments for expression in mammalian cells were cloned using a
TOPO cloning kit, digested with SalI and NotI, and introduced into the
corresponding sites of the VRC vector.
The plasmids pDEST17-SAR-M-TEV63AA and pDEST17-SAR-M-
TEV116AA, carrying the C-terminal 63 and 116 amino acids of M
protein, respectively, and with a His-tags, were constructed by a
commercial service (Invitrogen). To construct pQE2-M116, which
carries an alternative version of M116 as a His-tagged protein,
pDEST17-SAR-M-TEV116AAwas used as a template for PCR ampliﬁca-
tion using the primer pair indicated in Table S1 and Taq polymerase.
The PCR product was cloned using a TOPO cloning kit, and, following
conﬁrmation of the sequence, the insert was removed by digestion
with NdeI and NotI and subcloned into the corresponding sites of
pQE2 vector (Qiagen).
The plasmid VRC8301 carrying codon-optimized M was kindly
provided by Dr. Nabel (Huang et al., 2004). To construct the plasmid
pcDNA4/HisMaxB-hM116 for expression of M116 protein in mamma-
lian cells, the corresponding DNA fragment was ampliﬁed by PCR
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and Pfx polymerase. The PCR product was cloned into pCR-BluntII
(Invitrogen), and the resulting plasmid was introduced into TOP10.
After conﬁrmation of the sequence, the fragment was excised by
digestion with EcoRI and NotI and subcloned into the corresponding
sites of pcDNA4/HisMaxB (Invitrogen).
Expression and puriﬁcation of the N and M proteins
All recombinant proteins were afﬁnity-puriﬁed using the His-tag
introduced into the protein, and His-tags in the proteins used for
biochemical analyses were removed enzymatically according to the
manufacturer's instructions (see Supplement 1 for details).
Preparation of antibodies against N and M proteins
Aliquots of 100 μg of puriﬁed N or M63 were used for
immunization of rabbits with Freund's adjuvant (Difco). To prepare
afﬁnity-puriﬁed antibodies, M116 or N was coupled to NHS-activated
sepharose (GE Healthcare) in accordance with the manufacturer's
instructions. Then, 8 mL of serum was applied to each column, which
was washed with 2CV of PBST. The antibody was eluted with 2 CV of
0.1 M glycine–HCl (pH 2.5), and the fractions were immediately
neutralized with 1 M Tris–HCl (pH 8.8).
Mapping of the M protein binding site on the N protein
A set of 42 overlapping peptides (N70% purity) spanning the entire
sequence of the N protein, each consisting of 15 amino acids
overlapping the next peptide by 5 amino acids, were prepared by a
commercial service (Biologica). The interaction of each of these
peptides with M protein was assayed by an ELISA-based method.
Brieﬂy, the peptides (10 μg/mL) were immobilized onto the wells of a
96-well microtiter plate (Corning) by incubation in 50 mM carbonate
buffer (pH 9.0) containing 1 mM of the chemical cross-linker
disuccinimidyl suberate (DSS; Pierce) at 37 °C for 1 h. After blocking
with Superblock (Pierce), the plate was incubated for 0.5 h with 1 μg/
mL ofM63 diluted in PBST, andwashed three timeswith PBST. Binding
of M63 was detected with the rabbit anti-M63 serum described above
in combination with HRP-goat anti-rabbit IgG (GE Healthcare) and
TMB (BioRad).
Surface plasmon response (SPR) analysis
The interactions of peptides derived from N protein with M116
were analyzed using a Biacore 3000 dual ﬂow cell (Biacore). M116 was
immobilized on a CM5 sensor chip by amine coupling at the level of
5500 response units (RU). As a negative control, a ﬂow cell was
immobilized with Tris–HCl at a parallel level. The response was the
direct indication of the amount of analyte bound. The running and
sample buffers were HBS-EP (Biacore). The analyte (70 μL) was
injected at 100 s followed by a dissociation phase (300 s). Each ﬂow
cell was regenerated with 10 μL of 0.1% SDS. All experiments were
carried out at a constant system ﬂow rate of 20 μL/min at 25 °C.
Analysis of M–N binding by ELISA
The interaction of M protein with several N mutant proteins was
analyzed by ELISA as described above with minor modiﬁcations.
Brieﬂy, N mutant proteins (0.01–10 μg/mL) were immobilized onto
plates with 50 mM carbonate buffer (pH 9.0) for 1 h at 37 °C. After
blocking, M116 (1 μg/mL) was added for 0.5 h, and binding of M116
was detected with anti-M63 rabbit serum. To analyze the competition
of N peptide (101–115) with N in the interaction between N and M, N
(1 μg/mL) was immobilized onto the microplates as describe above.
Separately, M63 (1 μg/mL) was incubated with peptides (N90% purity)for 0.5 h and added to the plates blocked for 0.5 h. Binding of M63 was
detected as described above.
Immunoprecipitation
HEK293 cells were maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM), containing 10% fetal bovine serum. One day before
transfection, aliquots of 3×106 cells were placed in 10-cm dishes, and
the cells were subsequently transfected with 4 μg of each plasmid
using FuGENE 6 transfection reagent (Roche). After 3 days, the cells
were washed with PBS, freeze-thawed in 1 ml of PBST, sonicated for
1min, and centrifuged at 15,000 ×g for 5min at 4 °C. Each supernatant
was mixed with 30 μL of Protein G Sepharose 4 Fast Flow (GE
Healthcare) and rotated for 1 h at 4 °C, and centrifuged. Each
supernatant was divided into 3 portions, to which were added 10 μg of
afﬁnity-puriﬁed anti-N-antibody, anti-M-antibody, or control serum.
Following rotation for 4 h at 4 °C, 30 μL of Protein G Sepharose was
added to each, and themixtures were rotated for 1 h at 4 °C. The beads
were washed 3 times with cold PBST and treated with SDS-PAGE
buffer.
Pseudoparticle production and density gradient analysis
Pseudoparticle production was performed as described (Huang et
al., 2004). Brieﬂy, 293 cells transfected as described above were
harvested, freeze-thawed three times in PBS, and pelleted in 15-mL
conical tubes by centrifugation at 3100 rpm. Each cleared lysate was
mixed with 2.5 mL of OptiPrep (Axis-Shield) and a density gradient
was formed by centrifugation at 60,000 rpm for 3 h in a VTI65.2 rotor
(Beckman). The fractions separated were subjected to immunoblot-
ting using rabbit anti-M63 or rabbit anti-N serum.
Analysis of pseudoparticle formation by electron microscopy
Transfected 293 cells were harvested from plates by pipetting with
DMEM and pelleted in 15-mL conical tubes by centrifugation at
1000 rpm. The supernatant was removed and 1 mL of ﬁxing solution
(0.2 M cacodylate buffer, pH 7.4, 3% glutaraldehyde, and 3% formal-
dehyde) was added. The specimens were mixed gently and analyzed
using a TEM system (Hitachi) to visualize the pseudoparticles.
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